These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
63. Targeting B-cell germlines and focusing affinity maturation: the next hurdles in HIV-1-vaccine development? Medina-Ramírez M; Sanders RW; Klasse PJ Expert Rev Vaccines; 2014 Apr; 13(4):449-52. PubMed ID: 24606603 [TBL] [Abstract][Full Text] [Related]
64. All eyes on the next generation of HIV vaccines: strategies for inducing a broadly neutralizing antibody response. Ahlers JD Discov Med; 2014 Apr; 17(94):187-99. PubMed ID: 24759623 [TBL] [Abstract][Full Text] [Related]
65. Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants. Martinez DR; Tu JJ; Kumar A; Mangold JF; Mangan RJ; Goswami R; Giorgi EE; Chen J; Mengual M; Douglas AO; Heimsath H; Saunders KO; Nicely NI; Eudailey J; Hernandez G; Morgan-Asiedu PK; Wiehe K; Haynes BF; Moody MA; LaBranche C; Montefiori DC; Gao F; Permar SR mBio; 2020 Mar; 11(2):. PubMed ID: 32156815 [TBL] [Abstract][Full Text] [Related]
66. Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env. Escolano A; Gristick HB; Gautam R; DeLaitsch AT; Abernathy ME; Yang Z; Wang H; Hoffmann MAG; Nishimura Y; Wang Z; Koranda N; Kakutani LM; Gao H; Gnanapragasam PNP; Raina H; Gazumyan A; Cipolla M; Oliveira TY; Ramos V; Irvine DJ; Silva M; West AP; Keeffe JR; Barnes CO; Seaman MS; Nussenzweig MC; Martin MA; Bjorkman PJ Sci Transl Med; 2021 Nov; 13(621):eabk1533. PubMed ID: 34818054 [TBL] [Abstract][Full Text] [Related]
67. CD4+ T Cells Are Dispensable for Induction of Broad Heterologous HIV Neutralizing Antibodies in Rhesus Macaques. Sarkar S; Spencer DA; Barnette P; Pandey S; Sutton WF; Basu M; Burch RE; Cleveland JD; Rosenberg AF; Rangel-Moreno J; Keefer MC; Hessell AJ; Haigwood NL; Kobie JJ Front Immunol; 2021; 12():757811. PubMed ID: 34745131 [TBL] [Abstract][Full Text] [Related]
68. Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. Costa MR; Pollara J; Edwards RW; Seaman MS; Gorny MK; Montefiori DC; Liao HX; Ferrari G; Lu S; Wang S J Virol; 2016 Nov; 90(22):10362-10378. PubMed ID: 27630232 [TBL] [Abstract][Full Text] [Related]
69. Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers. Nyanhete TE; Edwards RJ; LaBranche CC; Mansouri K; Eaton A; Dennison SM; Saunders KO; Goodman D; Janowska K; Spreng RL; Zhang L; Mudrak SV; Hope TJ; Hora B; Bradley T; Georgiev IS; Montefiori DC; Acharya P; Tomaras GD Front Immunol; 2021; 12():670561. PubMed ID: 35003053 [TBL] [Abstract][Full Text] [Related]
71. Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation. Kumar R; Tuen M; Li H; Tse DB; Hioe CE Vaccine; 2011 Nov; 29(48):9064-74. PubMed ID: 21945958 [TBL] [Abstract][Full Text] [Related]
73. Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model. Voss JE; Andrabi R; McCoy LE; de Val N; Fuller RP; Messmer T; Su CY; Sok D; Khan SN; Garces F; Pritchard LK; Wyatt RT; Ward AB; Crispin M; Wilson IA; Burton DR Cell Rep; 2017 Oct; 21(1):222-235. PubMed ID: 28978475 [TBL] [Abstract][Full Text] [Related]
74. mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice. Mu Z; Wiehe K; Saunders KO; Henderson R; Cain DW; Parks R; Martik D; Mansouri K; Edwards RJ; Newman A; Lu X; Xia SM; Eaton A; Bonsignori M; Montefiori D; Han Q; Venkatayogi S; Evangelous T; Wang Y; Rountree W; Korber B; Wagh K; Tam Y; Barbosa C; Alam SM; Williams WB; Tian M; Alt FW; Pardi N; Weissman D; Haynes BF Cell Rep; 2022 Mar; 38(11):110514. PubMed ID: 35294883 [TBL] [Abstract][Full Text] [Related]
75. Innovative approaches to track lymph node germinal center responses to evaluate development of broadly neutralizing antibodies in human HIV vaccine trials. Patricia D'Souza M; Allen MA; Baumblatt JAG; Boggiano C; Crotty S; Grady C; Havenar-Daughton C; Heit A; Hu DJ; Kunwar N; McElrath MJ; Vaccine; 2018 Sep; 36(38):5671-5677. PubMed ID: 30097219 [TBL] [Abstract][Full Text] [Related]
76. Cross-Reactivity to Kynureninase Tolerizes B Cells That Express the HIV-1 Broadly Neutralizing Antibody 2F5. Finney J; Yang G; Kuraoka M; Song S; Nojima T; Verkoczy L; Kitamura D; Haynes BF; Kelsoe G J Immunol; 2019 Dec; 203(12):3268-3281. PubMed ID: 31732530 [TBL] [Abstract][Full Text] [Related]
77. A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. Walker LM; Simek MD; Priddy F; Gach JS; Wagner D; Zwick MB; Phogat SK; Poignard P; Burton DR PLoS Pathog; 2010 Aug; 6(8):e1001028. PubMed ID: 20700449 [TBL] [Abstract][Full Text] [Related]
78. Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting. Cheng C; Xu K; Kong R; Chuang GY; Corrigan AR; Geng H; Hill KR; Jafari AJ; O'Dell S; Ou L; Rawi R; Rowshan AP; Sarfo EK; Sastry M; Saunders KO; Schmidt SD; Wang S; Wu W; Zhang B; Doria-Rose NA; Haynes BF; Scorpio DG; Shapiro L; Mascola JR; Kwong PD PLoS One; 2019; 14(4):e0215163. PubMed ID: 30995238 [TBL] [Abstract][Full Text] [Related]
79. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Jardine JG; Kulp DW; Havenar-Daughton C; Sarkar A; Briney B; Sok D; Sesterhenn F; Ereño-Orbea J; Kalyuzhniy O; Deresa I; Hu X; Spencer S; Jones M; Georgeson E; Adachi Y; Kubitz M; deCamp AC; Julien JP; Wilson IA; Burton DR; Crotty S; Schief WR Science; 2016 Mar; 351(6280):1458-63. PubMed ID: 27013733 [TBL] [Abstract][Full Text] [Related]